$276.94
6.872.54%
At Close: -
$276.94
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Bio-Rad Laboratories reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Bio-Rad Laboratories using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
BIO | Bio-Rad Laboratories | $3.00 | $2.01 | — | — | $681.10M | $645.79M | — | — | 08/01/2024 | Get Alert |
BIO | Bio-Rad Laboratories | $3.34 | $2.15 | $2.29 | 6.51% | $676.84M | $619.09M | $610.82M | -1.34% | 05/07/2024 | Get Alert |
BIO | Bio-Rad Laboratories | $3.31 | $2.82 | $3.10 | 9.93% | $730.29M | $685.09M | $681.18M | -0.57% | 02/15/2024 | Get Alert |
BIO | Bio-Rad Laboratories | $2.64 | $2.78 | $2.33 | -16.19% | $680.80M | $689.57M | $632.12M | -8.33% | 10/26/2023 | Get Alert |
BIO | Bio-Rad Laboratories | $3.38 | $2.55 | $3.00 | 17.65% | $691.10M | $687.88M | $681.10M | -0.99% | 08/03/2023 | Get Alert |
BIO | Bio-Rad Laboratories | $4.94 | $3.54 | $3.34 | -5.65% | $700.06M | $689.83M | $676.84M | -1.88% | 05/04/2023 | Get Alert |
BIO | Bio-Rad Laboratories | $3.21 | $3.45 | $3.31 | -4.06% | $732.77M | $742.25M | $730.29M | -1.61% | 02/16/2023 | Get Alert |
BIO | Bio-Rad Laboratories | $3.71 | $2.78 | $2.60 | -6.47% | $715.20M | $679.94M | $680.80M | 0.13% | 10/27/2022 | Get Alert |
BIO | Bio-Rad Laboratories | $3.54 | $2.80 | $3.38 | 20.71% | $715.93M | $682.62M | $691.10M | 1.24% | 07/28/2022 | Get Alert |
BIO | Bio-Rad Laboratories | $5.21 | $3.40 | $4.94 | 45.29% | $726.80M | $675.10M | $700.06M | 3.70% | 04/28/2022 | Get Alert |
BIO | Bio-Rad Laboratories | $4.01 | $2.85 | $3.21 | 12.63% | $789.84M | $731.98M | $732.77M | 0.11% | 02/10/2022 | Get Alert |
BIO | Bio-Rad Laboratories | $3.00 | $2.44 | $3.71 | 52.05% | $647.26M | $661.87M | $715.20M | 8.06% | 10/28/2021 | Get Alert |
BIO | Bio-Rad Laboratories | $1.61 | $2.66 | $3.54 | 33.08% | $536.88M | $631.78M | $715.93M | 13.32% | 07/29/2021 | Get Alert |
BIO | Bio-Rad Laboratories | $1.91 | $3.00 | $5.21 | 73.67% | $571.64M | $660.98M | $726.80M | 9.96% | 04/29/2021 | Get Alert |
BIO | Bio-Rad Laboratories | $2.32 | $3.29 | $4.01 | 21.88% | $624.43M | $686.80M | $789.84M | 15.00% | 02/11/2021 | Get Alert |
BIO | Bio-Rad Laboratories | $1.61 | $1.80 | $3.00 | 66.67% | $560.63M | $570.58M | $647.26M | 13.44% | 10/29/2020 | Get Alert |
BIO | Bio-Rad Laboratories | $1.57 | $1.15 | $1.61 | 40.00% | $572.62M | $503.82M | $536.88M | 6.56% | 07/30/2020 | Get Alert |
BIO | Bio-Rad Laboratories | $1.65 | $1.61 | $1.91 | 18.63% | $553.98M | $554.89M | $571.64M | 3.02% | 05/06/2020 | Get Alert |
BIO | Bio-Rad Laboratories | $2.13 | $2.44 | $2.32 | -4.92% | $617.54M | $641.95M | $624.43M | -2.73% | 02/13/2020 | Get Alert |
BIO | Bio-Rad Laboratories | $0.91 | $1.40 | $1.61 | 15.00% | $545.14M | $565.03M | $560.63M | -0.78% | 10/31/2019 | Get Alert |
BIO | Bio-Rad Laboratories | $1.64 | $1.33 | $1.57 | 18.05% | $575.91M | $566.19M | $572.62M | 1.14% | 08/01/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $2.29 | $2.15 | 6.51 % |
Dec 2023 | 2024-02-15 | $3.10 | $2.82 | 9.93 % |
Sep 2023 | 2023-10-26 | $2.33 | $2.78 | -16.2 % |
Jun 2023 | 2023-08-03 | $3.00 | $2.55 | 17.6 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $610.82M | $619.09M | -1.34 % |
Dec 2023 | 2024-02-15 | $681.18M | $685.09M | -0.57 % |
Sep 2023 | 2023-10-26 | $632.12M | $689.57M | -8.33 % |
Jun 2023 | 2023-08-03 | $681.10M | $687.88M | -0.99 % |
Bio-Rad Laboratories (BIO) is scheduled to report earnings on August 1, 2024. The last reported earnings were for reported on May 7, 2024 for Q1.
The Actual EPS was $2.29, which beat the estimate of $2.15.
The Actual Revenue was $610.8M, which missed the estimate of $619.1M.
Browse earnings estimates, EPS, and revenue on all stocks.